Nanoscope Therapeutics Inc., a US-based clinical-stage biotechnology company, announced on Monday that it has named Vicente Anido Jr, PhD as its new strategic advisor to the company's board and management.
Dr Anido Jr has more than three decades of ophthalmic experience. He has served as chief executive officer and chairman at Aerie Pharmaceuticals. He has worked in various companies including his role as chief executive officer at ISTA Pharmaceuticals.
Sulagna Bhattacharya, Nanoscope Therapeutics chief executive officer and co-founder, said, 'We are pleased to have Vince join our team of advisors. His deep experience and accomplishments in building and commercialising profitable ophthalmic companies will provide valuable guidance to support our clinical and corporate strategy. We look forward to leveraging his expertise as we advance Nanoscope's platform of optogenetic therapies to restore vision in sufferers of inherited retinal degenerative diseases.'
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer